In her new role as president of Cell Therapeutics (CTI) Europe, Dr Waters, will accelerate the launch of Ap(3)ana, an organization that will seek to integrate new technologies in the areas of informatics, genetics, preclinical and clinical development to advance medical treatment and predictive medicine.
Most recently, Dr Waters has served as president and COO of Tyr Pharma. She holds a PhD in genetics from the University of California, an MBA from University of California’s, Los Angeles Anderson School of Management, and a BS in biology from San Diego State University.
James Bianco, CEO of CTI, said: “With her specialized background in genomics, hands on experience in integrating R&D operations, and proven strategic portfolio development capabilities. She will bring the necessary knowledge and experience in oncology to direct Bresso’s world-class scientists and bridge R&D with translational medicine.”